GSK’s recently acquired Nuvalent asset produced early regulatory payoff as the FDA approved zidesamtinib, now marketed as Jideytro, for ROS1-positive advanced or metastatic non-small-cell lung cancer after prior ROS1 inhibitor therapy. The clearance arrived ahead of a scheduled deadline, following designations that can accelerate reviews. The approval follows GSK’s $10.6 billion acquisition of Nuvalent, highlighting how quickly investors are seeking returns from mega-deals. While commercial expectations remain uncertain given the competitive landscape of ROS1-targeted therapies, the approval gives GSK a new oncology revenue lever and supports the company’s push to expand beyond its core franchises. For the biotech sector, the sequence reinforces how acquirers can convert late-stage assets into rapid regulatory milestones—and how the FDA review cadence continues to reward breakthrough-orphan priority pathways.